Pfizer Inc. (PFE) Stake Lowered by Carmichael Hill & Associates Inc.

Carmichael Hill & Associates Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,219 shares of the biopharmaceutical company’s stock after selling 956 shares during the quarter. Carmichael Hill & Associates Inc.’s holdings in Pfizer were worth $621,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PFE. Advocacy Wealth Management Services LLC raised its position in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 258 shares in the last quarter. Contravisory Investment Management Inc. increased its position in Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 745 shares during the period. Vestor Capital LLC acquired a new position in Pfizer during the third quarter worth approximately $53,000. Arlington Partners LLC increased its position in Pfizer by 64.7% during the fourth quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 841 shares during the period. Finally, Highwater Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth approximately $123,000. 69.49% of the stock is owned by hedge funds and other institutional investors.

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald set a $53.00 target price on Pfizer and gave the company a “buy” rating in a report on Sunday, December 30th. Credit Suisse Group set a $45.00 target price on Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 1st. UBS Group downgraded Pfizer from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 23rd. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $45.61.

Shares of NYSE:PFE traded up $0.36 on Friday, hitting $39.97. The company had a trading volume of 18,142,883 shares, compared to its average volume of 24,498,510. The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52. Pfizer Inc. has a 52-week low of $34.37 and a 52-week high of $46.47. The company has a market capitalization of $234.57 billion, a P/E ratio of 13.32, a P/E/G ratio of 2.38 and a beta of 0.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The business’s revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.62 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.44 annualized dividend and a yield of 3.60%. Pfizer’s payout ratio is currently 48.00%.

In other Pfizer news, insider Rady A. Johnson sold 8,700 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the sale, the insider now directly owns 59,797 shares in the company, valued at $2,459,450.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mikael Dolsten sold 100,471 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $43.56, for a total value of $4,376,516.76. Following the sale, the insider now owns 390,097 shares of the company’s stock, valued at $16,992,625.32. The disclosure for this sale can be found here. Insiders sold 332,526 shares of company stock valued at $14,346,539 over the last quarter. Insiders own 0.09% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/carmichael-hill-associates-inc-sells-956-shares-of-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: What are the FAANG Stocks?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.